BMJ Open 2013;3:e003135 doi:10.1136/bmjopen-2013-003135
Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.
A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
Glynn RJ и другие
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
Если статин добавить к НМГ при лечении ТГВ, то что будет?:
Vasa. 2016 Apr;45(2):133-40.
Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis.
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study.
Thromb Haemost. 2016 Jan 28;115(6). [Ссылки могут видеть только зарегистрированные и активированные пользователи]
The Association of Statin Therapy with the Risk of Recurrent Venous Thrombosis.
J Thromb Haemost. 2016 Apr 8. [Ссылки могут видеть только зарегистрированные и активированные пользователи]
О возможном антитромботическом механизме статинов на примере розувастатина:
Patients were randomized to rosuvastatin 20 mg/day for 4 weeks or no intervention. Blood was drawn at baseline and at end of study. The primary outcome was factor (F) VIII:C. In total, five coagulation factors were measured: FVIII:C, von Willebrand factor:Ag, FVII:C, FXI:C, and D-dimer. Among 247 randomized participants, mean age was 58 years, 62% were women and 49% had unprovoked VT. For all tested coagulation factors, mean levels were clearly decreased at end of study in rosuvastatin users, whereas they hardly differed in non-statin users. Results were most consistent for FVIII:C where mean FVIII:C levels were 7.2 IU/dL [95% CI (confidence interval) 2.9-11.5] lower in rosuvastatin users, while among non-users, no change in FVIII:C was observed (mean difference -0.1; 95% CI -3.0 to 2.9). The mean age and sex adjusted difference in FVIII:C change was -6.7 IU/dL (95% CI -12.0 to -1.4) in rosuvastatin users vs. non-users. Subgroup analyses revealed that the decrease in coagulation factors by rosuvastatin was more pronounced in participants with unprovoked VT and in those with cardiovascular risk factors.
---
Eur Heart J. 2018 Jan 30.
Rosuvastatin use improves measures of coagulation in patients with venous thrombosis.
Biedermann JS и соавт. [Ссылки могут видеть только зарегистрированные и активированные пользователи]